| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Damps T et al. | The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment. | 2017 | PLoS ONE | pmid:28859143 |
| Asche CV et al. | Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States. | 2016 Mar-Apr | Value Health | pmid:27021759 |
| Zane C et al. | A Randomized Split-Face Clinical Trial of Photodynamic Therapy with Methyl Aminolevulinate versus Ingenol Mebutate Gel for the Treatment of Multiple Actinic Keratoses of the Face and Scalp. | 2016 | Dermatology (Basel) | pmid:27578305 |
| Mühlstädt M | Ingenol Mebutate vs. Daylight Photodynamic Therapy in a Kidney Transplant Recipient. | 2016 | Dermatology (Basel) | pmid:27513345 |
| Erlendsson AM et al. | Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice. | 2016 | PLoS ONE | pmid:27636884 |
| Emmert S et al. | Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate. | 2016 | PLoS ONE | pmid:27612149 |
| Liu M et al. | Synthesis and Cytotoxicity against K562 Cells of 3-O-Angeloyl-20-O-acetyl Ingenol, a Derivative of Ingenol Mebutate. | 2016 | Int J Mol Sci | pmid:27548156 |
| Mohanna MT and Hofbauer GF | Bowenoid Actinic Keratosis and Bowen's Disease Treated Successfully with Ingenol Mebutate. | 2016 | Dermatology (Basel) | pmid:27513957 |
| Mainetti C et al. | Successful Treatment of Relapsing Bowen's Disease with Ingenol Mebutate: The Use of Dermoscopy to Monitor the Therapeutic Response. | 2016 | Dermatology (Basel) | pmid:27513936 |
| Gaide O et al. | Ingenol Mebutate 500 μg for Treatment of the Scalp in Refractory Field Cancerization. | 2016 | Dermatology (Basel) | pmid:27513862 |
| Gaide O and Cattin V | Ingenol Mebutate 500 µg on the Cheekbones with Concomitant Conjunctivitis. | 2016 | Dermatology (Basel) | pmid:27513756 |
| Tzika E et al. | Ingenol Mebutate for Recalcitrant Chronic Actinic Cheilitis. | 2016 | Dermatology (Basel) | pmid:27513668 |
| Stieger M and Hunger RE | Ingenol Mebutate Treatment in a Patient with Gorlin Syndrome. | 2016 | Dermatology (Basel) | pmid:27513585 |
| Gadaldi K et al. | Ingenol Mebutate for Lentigo Maligna: A Case Report. | 2016 | Dermatology (Basel) | pmid:27513527 |
| Alkhalaf A and Hofbauer GF | Ingenol Mebutate 150 mg as Physician-Directed Treatment of Bowen's Disease Under Occlusion. | 2016 | Dermatology (Basel) | pmid:27512986 |
| Le TT et al. | IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate. | 2016 | PLoS ONE | pmid:27100888 |
| Stockfleth E et al. | New Topical Treatment Options for Actinic Keratosis: A Systematic Review. | 2016 | Acta Derm. Venereol. | pmid:26068001 |
| Bhandari PR and Pai VV | Could ingenol mebutate be useful in managing nonmelanoma skin cancers? | 2015 Apr-Jun | Indian J Cancer | pmid:26853424 |
| De Felice B et al. | Ingenol mebutate treatment in keloids. | 2015 | BMC Res Notes | pmid:26391582 |
| Pellacani G et al. | A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. | 2015 | J Eur Acad Dermatol Venereol | pmid:26300464 |
| Jiang G et al. | Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. | 2015 | PLoS Pathog. | pmid:26225771 |
| Freiberger SN et al. | Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. | 2015 | Mol. Cancer Ther. | pmid:26116359 |
| Soini EJ et al. | Cost-utility of first-line actinic keratosis treatments in Finland. | 2015 | Adv Ther | pmid:26006101 |
| Cantisani C et al. | Evaluation of Ingenol mebutate efficacy for the treatment of actinic keratosis with Antera 3D camera. | 2015 | Eur Rev Med Pharmacol Sci | pmid:25635981 |
| Edwards SK et al. | N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma. | 2013 | BMC Cancer | pmid:24131623 |
| Song X et al. | RasGRPs are targets of the anti-cancer agent ingenol-3-angelate. | 2013 | PLoS ONE | pmid:23991094 |
| Cozzi SJ et al. | Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. | 2013 | Arch. Dermatol. Res. | pmid:22871992 |
| Liang X et al. | Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer. | 2013 | Bioorg. Med. Chem. Lett. | pmid:23993332 |
| Doan HQ et al. | Ingenol mebutate: potential for further development of cancer immunotherapy. | 2012 | J Drugs Dermatol | pmid:23134979 |
| Lebwohl M et al. | Ingenol mebutate gel for actinic keratosis. | 2012 | N. Engl. J. Med. | pmid:22417254 |
| Fallen RS and Gooderham M | Ingenol mebutate: an introduction. | 2012 | Skin Therapy Lett. | pmid:22358305 |
| Cozzi SJ et al. | Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. | 2012 | J. Invest. Dermatol. | pmid:22189786 |
| Lee WY et al. | Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta. | 2010 | J. Biol. Chem. | pmid:20472553 |
| Li L et al. | The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. | 2010 | Cancer Res. | pmid:20460505 |
| Ghoul A et al. | Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. | 2009 | Cancer Res. | pmid:19417139 |
| Benhadji KA et al. | Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. | 2008 | Br. J. Cancer | pmid:19034280 |
| Serova M et al. | Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. | 2008 | Mol. Cancer Ther. | pmid:18413805 |
| Challacombe JM et al. | Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. | 2006 | J. Immunol. | pmid:17114487 |
| Cozzi SJ et al. | Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. | 2006 | Cancer Res. | pmid:17047072 |
| Hampson P et al. | PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. | 2005 | Blood | pmid:15845901 |
| Gillespie SK et al. | Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. | 2004 | Mol. Cancer Ther. | pmid:15634659 |
| Ogbourne SM et al. | Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. | 2004 | Cancer Res. | pmid:15087400 |
| pmid: | ||||
| pmid:27567085 | ||||
| pmid:27550505 | ||||
| pmid:25820019 | ||||
| pmid:25795391 | ||||
| pmid:23231025 | ||||
| pmid:23134983 | ||||
| pmid:22828167 |
Ingenol 3-angelate
Ingenol 3-angelate is a lipid of Fatty Acyls (FA) class.
Cross Reference
